L’immunocytochimie dans le diagnostic différentiel des pleurésies et ascites

Butnor, 2006, My approach to the diagnosis of mesothelial lesions, J Clin Pathol, 59, 564, 10.1136/jcp.2005.029652 Chu, 2002, Expression of Cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases, Mod Pathol, 15, 6, 10.1038/modpathol.3880483 Chu, 2005, Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma, Mod Pathol, 18, 105, 10.1038/modpathol.3800259 Ordonez, 2003, Value of mesothelin immunostaining in the diagnosis of mesothelioma, Mod Pathol, 16, 192, 10.1097/01.MP.0000056981.16578.C3 Galateau-Sallé F, Copin MC, Delajartre AY, Vignaud JM, Astoul P, Pairon JC et al. Quels critères pour le diagnostic anatomopathologique du mésothéliome pleural malin ? in : Recommandations de la Société de Pneumologie de Langue Française sur le mésothéliome pleural. Conférence d’experts. Rev Mal Respir 2006 ; 23: 11537-44. Kushitani, 2007, Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma, Mod Pathol, 57, 190 Ng, 2002, Thyroid Transcription Factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion fluid cytology specimens. A study of 36 cases, Cancer Cytopathol, 96, 43, 10.1002/cncr.10310 Belleannée, 2004, Tumeurs sans primitif connu : place de l’immunohistochimie, Oncologie, 6, 252, 10.1007/s10269-004-0056-1